Please login to the form below

Not currently logged in
Email:
Password:

Eduardo Bravo becomes head of EBE

TiGenix CEO appointed president of the EBE’s board of directors

The European Biopharmaceutical Enterprises (EBE) has appointed Eduardo Bravo as president of its board of directors for the 2016-2018 term.

Bravo graduates to the leadership role of the European trade association from his previous position as its vice president.

He said: “This is a very exciting time at the EBE. We are well positioned to help new initiatives and cutting-edge technologies advance biopharmaceutical pipelines toward eventual solutions for difficult-to-treat conditions and diseases.

“It is a pleasure to be working with such a dedicated group of senior industry leaders to support emerging sciences in the search of therapeutic solutions.”

Bravo has over 25 years of experience in the biopharmaceutical industry, and is a member of the executive committee of the Alliance for Regenerative Medicine (ARM).

He currently serves as chief executive officer of TiGenix, a biopharma company based in Belgium, and prior to this served as Cellerix's chief executive officer between 2006 and 2011.

Barbara Freischem, EBE's executive director, said: “Mr Bravo brings so much to our organisation. 

“Coming from the field of advanced therapies, he helps bridge the gap between the lab and personalised medicines within a thriving and innovative ecosystem.”

28th June 2016

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics